Biomarkers as Putative Therapeutic Targets in Colorectal Cancer

2021 ◽  
pp. 123-177
Author(s):  
Sonali Pal ◽  
Manoj Garg ◽  
Amit Kumar Pandey
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets

scholarly journals Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes

Cancers ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 983 ◽  
Author(s):  
Otília Menyhart ◽  
Tatsuhiko Kakisaka ◽  
Lőrinc Sándor Pongor ◽  
Hiroyuki Uetake ◽  
Ajay Goel ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Gene Expression Data ◽  
Drug Targets ◽  
Therapeutic Targets ◽  
Independent Set ◽  
Driver Mutations ◽  
Expression Data ◽  
Expression Levels ◽  
Mutational Status

Background: Numerous driver mutations have been identified in colorectal cancer (CRC), but their relevance to the development of targeted therapies remains elusive. The secondary effects of pathogenic driver mutations on downstream signaling pathways offer a potential approach for the identification of therapeutic targets. We aimed to identify differentially expressed genes as potential drug targets linked to driver mutations. Methods: Somatic mutations and the gene expression data of 582 CRC patients were utilized, incorporating the mutational status of 39,916 and the expression levels of 20,500 genes. To uncover candidate targets, the expression levels of various genes in wild-type and mutant cases for the most frequent disruptive mutations were compared with a Mann–Whitney test. A survival analysis was performed in 2100 patients with transcriptomic gene expression data. Up-regulated genes associated with worse survival were filtered for potentially actionable targets. The most significant hits were validated in an independent set of 171 CRC patients. Results: Altogether, 426 disruptive mutation-associated upregulated genes were identified. Among these, 95 were linked to worse recurrence-free survival (RFS). Based on the druggability filter, 37 potentially actionable targets were revealed. We selected seven genes and validated their expression in 171 patient specimens. The best independently validated combinations were DUSP4 (p = 2.6 × 10−12) in ACVR2A mutated (7.7%) patients; BMP4 (p = 1.6 × 10−04) in SOX9 mutated (8.1%) patients; TRIB2 (p = 1.35 × 10−14) in ACVR2A mutated patients; VSIG4 (p = 2.6 × 10−05) in ANK3 mutated (7.6%) patients, and DUSP4 (p = 7.1 × 10−04) in AMER1 mutated (8.2%) patients. Conclusions: The results uncovered potentially druggable genes in colorectal cancer. The identified mutations could enable future patient stratification for targeted therapy.

scholarly journals Screening of potential diagnostic markers and therapeutic targets against colorectal cancer

2015 ◽  
pp. 1691 ◽  
Author(s):  
Jing Yuan Fang ◽  
XiaoQing Tian ◽  
DanFeng Sun ◽  
ShuLiang Zhao ◽  
Hua Xiong
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets ◽  
Diagnostic Markers

scholarly journals MiR-429 Involves in the Pathogenesis of Colorectal Cancer via Directly Targeting LATS2

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Xia Chen ◽  
Ai-li Wang ◽  
Yuan-yuan Liu ◽  
Chen-xi Zhao ◽  
Xue Zhou ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Solid Tumors ◽  
Therapeutic Targets ◽  
Multiple Cancer ◽  
Upstream Regulator ◽  
The World ◽  
Cancer Types ◽  
Metastasis Rate ◽  
Direct Regulator

Colorectal cancer (CRC) is a leading cause of cancer-related death around the world whose recurrence and metastasis rate is high. Due to the underlying unclear pathogenesis, it is hard so far to predict the tumorigenesis and prevent its recurrence. YAP/TAZ has been reported to be activated and functioned as a potential oncogene in multiple cancer types and proved to be essential for the carcinogenesis of most solid tumors. In the present study, we found that YAP/TAZ was markedly upregulated in CRC tissues comparing with the adjacent noncancerous tissues due to the downregulation of LATS2, the main upstream regulator. We further identified miR-429 as a direct regulator of LATS2-YAP/TAZ activation, suggesting that the miR-429-LATS2-YAP/TAZ might be novel effective diagnostic axis and therapeutic targets for CRC.

scholarly journals Potential Therapeutic Targets of B7 Family in Colorectal Cancer

2020 ◽  
Vol 11 ◽  
Author(s):  
Changgang Wang ◽  
Haoran Feng ◽  
Xi Cheng ◽  
Kun Liu ◽  
Dongli Cai ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets ◽  
B7 Family

scholarly journals Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer

2016 ◽  
Vol 25 (3) ◽  
pp. 190-199 ◽  
Author(s):  
Sean M. Ronnekleiv-Kelly ◽  
Richard A. Burkhart ◽  
Timothy M. Pawlik
Keyword(s):  
Colorectal Cancer ◽  
Molecular Markers ◽  
Metastatic Colorectal Cancer ◽  
Therapeutic Targets

Abstract 1078: Micro RNAs as promising therapeutic targets for anti-metastatic therapy in colorectal cancer

2016 ◽  
Author(s):  
Takashi Kawai ◽  
Takeshi Nagasaka ◽  
Yoshiko Mori ◽  
Tomokazu Fuji ◽  
Fumitaka Taniguchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Therapeutic Targets ◽  
Micro Rnas

Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3589-3589
Author(s):  
Christopher Hanyoung Lieu ◽  
Erica Golemis ◽  
Jihye Kim ◽  
Ilya Serebriiskii ◽  
Mark Bailey ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Young Patients ◽  
Therapeutic Targets ◽  
Genomic Landscape
Sign in / Sign up

Export Citation Format

Share Document